These clinical trials test therapies for which a great
deal of excitement has been generated in the neurorehabilitation community by human physiological studies 3, 4 and smaller scale clinical trials. 5-11 2. Clinical trials in this area present special challenges that do not beset trials of pharmacological modalities. For example, it is virtually impossible to conduct a double-blind clinical trial of a physical intervention because the patient always knows what modality is being provided. The therapists who conduct the trial also are not blinded. Only the people who administer the outcome measures and functional tests are blinded to the treatment received by individual patients. Each study compensates for this limitation in different ways. Thus, these clinical trials may provide guidance in the design of future tests of physical rehabilitation modalities.
The administration of the therapies could vary with
the skill and training of the therapists. This situation is especially true in the SCILT study. Thus, there is a need to train the study participants to standardize the treatment. 4. There has been great skepticism about the effectiveness of rehabilitation treatments, in part because the rehabilitation community has been slow to subject its approaches to rigorous scientific testing. Of course, there are good reasons for the delay in adopting a standard of evidence-based practice, including many technical problems that are not experienced by most other fields of medicine. These problems address not only those already mentioned but also the difficulties in testing complex team approaches in which individual components are hard to evaluate in isolation. In addition, inclusion and exclusion criteria may be more difficult to delineate since the population is heterogeneous, that is, there is great variability in function. Results of such trials may not be generalizable to all patients within a diagnostic category. Regardless of the cause, the skepticism can be addressed by publication of the rationale and study design components in a format that is more comprehensive than is ordinarily the case in the reports of results of clinical trials. 5. Public specification of the primary outcome measures in advance of data collection and analysis eliminates concerns of selective reporting or retrospective interpretation of the data.
The therapies being tested by the EXCITE and SCILT protocols have important commonalities. Both involve the application of the theory of task specificity to the training of affected patients. [12] [13] [14] [15] Moreover, skill in the performance of a task requires active performance of that task and cannot be achieved by patterning through passive movement. Thus, if one wishes to improve walking (as in the SCILT), one must practice walking and not practice rowing (although some therapists believe there is a crossover effect when the same muscles are used in related activities, e.g., bicycling and walking). In addition, passive walking movements imposed by a therapist in a patient that is not bearing any of her or his own weight are not sufficient. Similarly, to improve performance in an impaired hand (as in the EXCITE trial), that hand must actively perform the tasks to be improved.
Both the SCILT and the EXCITE trial involve a high degree of specification of the movements to be made. The SCILT is based on the assumption that to practice correct walking, sensory feedback must be obtained from the feet in their correct position. Thus, therapists must be trained to guide the feet and legs in a standardized manner so that the patterns of sensory feedback and motor output are as close to normal as possible. Similarly, the EXCITE trial incorporates a high degree of task specificity. It is true that this trial encourages the stroke-affected arm and hand to perform random tasks of daily life by constraining the unaffected hand at least 90% of waking hours, and movements performed by the impaired hand during activities of daily living are determined by the patient, with some suggestions from the therapist and with patient participation in the behavioral contract. However, this approach combines a regimen of training, during which patients are taught how to accomplish specific tasks, with adaptive task practice through successive increments in difficulty (it will be interesting to see if tasks trained in this way improve more than activities of daily living carried out at the discretion of the patient). The analogous condition in the SCILT is a progressive increase in walking speed and weight support by the patient. Both trials involve an intervention group of patients treated in the subacute stage of their disorder. In the SCILT, the control group consists of patients treated with a conventional rehabilitation regimen.
In the EXCITE trial, the patients treated during the first 3 to 9 months poststroke are compared with a control group whose CI treatment is delayed at least 1 year. During this time, they receive "usual and customary" care, depending on their insurance and resources. Both studies include follow-up periods (1 year for SCILT, 2 years for EXCITE) to determine whether improvement is sustained. The investigators are to be commended for subjecting these important clinical trials to the scrutiny that will attend the publication of their protocols in advance of knowledge of the outcomes. By so doing, they are setting a standard of rigorous investigation in a very difficult field.
